Bleomycin-induced pulmonary hypertension: an underrated phenomenon with important implications in the setting of high-risk clinical scenarios
Main Article Content
Keywords
Bleomycin, pulmonary hypertension, implications, major surgery
References
1- Jayakrishnan B, Kausalya R, Al-Rashdi HA, et al. Bleomycin and perioperative care: a case report. Sarcoidosis Vasc Diffuse Lung Dis. 2023 Sep 13; 40(3):e2023030. doi: 10.36141/svdld.v40i3.14385.
2- Demirkol B, Gul S, Cörtük M, et al. Protective efficacy of pirfenidone in rats with pulmonary fibrosis induced by bleomycin. Sarcoidosis Vasc Diffuse Lung Dis. 2023 Sep 13 ;40(3):e2023036. doi: 10.36141/svdld.v40i3.13847.
3- Gürdoğan M, Demir M, Yalta K, Gülertop Y. Cancer Therapy-Related Pulmonary Hypertension: A Review of Mechanisms and Implications for Clinical Practice. Anatol J Cardiol. 2023; 27(6): 299-307. doi: 10.14744/AnatolJCardiol.2023.3013.
4- Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43(38): 3618-3731. doi: 10.1093/eurheartj/ehac237.
5- Ruffenach G, Hong J, Vaillancourt M, et al. Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights. Respir Res. 2020; 21(1): 303. doi: 10.1186/s12931-020-01570-2.
6- Singh N, Dorfmüller P, Shlobin OA, Ventetuolo CE. Group 3 Pulmonary Hypertension: From Bench to Bedside. Circ Res. 2022; 130(9): 1404-1422. doi: 10.1161/CIRCRESAHA.121.319970.
7- Yalta K, Yalta T, Gurdogan M, et al. Cardiac Biomarkers in the Setting of Asthma Exacerbations: a Review of Clinical Implications and Practical Considerations. Curr Allergy Asthma Rep. 2020; 20(6): 17. doi: 10.1007/s11882-020-00909-5.
2- Demirkol B, Gul S, Cörtük M, et al. Protective efficacy of pirfenidone in rats with pulmonary fibrosis induced by bleomycin. Sarcoidosis Vasc Diffuse Lung Dis. 2023 Sep 13 ;40(3):e2023036. doi: 10.36141/svdld.v40i3.13847.
3- Gürdoğan M, Demir M, Yalta K, Gülertop Y. Cancer Therapy-Related Pulmonary Hypertension: A Review of Mechanisms and Implications for Clinical Practice. Anatol J Cardiol. 2023; 27(6): 299-307. doi: 10.14744/AnatolJCardiol.2023.3013.
4- Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43(38): 3618-3731. doi: 10.1093/eurheartj/ehac237.
5- Ruffenach G, Hong J, Vaillancourt M, et al. Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights. Respir Res. 2020; 21(1): 303. doi: 10.1186/s12931-020-01570-2.
6- Singh N, Dorfmüller P, Shlobin OA, Ventetuolo CE. Group 3 Pulmonary Hypertension: From Bench to Bedside. Circ Res. 2022; 130(9): 1404-1422. doi: 10.1161/CIRCRESAHA.121.319970.
7- Yalta K, Yalta T, Gurdogan M, et al. Cardiac Biomarkers in the Setting of Asthma Exacerbations: a Review of Clinical Implications and Practical Considerations. Curr Allergy Asthma Rep. 2020; 20(6): 17. doi: 10.1007/s11882-020-00909-5.